Repositioning Candidates

Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3

Search for:

     depression
115 records.
Candidate ID Source ID Source Type Compound Type Candidate Name Inclusion Criteria
R1271 DB09253 withdrawn small molecule Safrazine Indication associated Details
R1272 DB09254 withdrawn small molecule Caroxazone Indication associated Details
R1293 DB09304 experimental small molecule Setiptiline Indication associated Details
R1294 DB09305 experimental small molecule Aptazapine Indication associated Details
R1295 DB09306 experimental small molecule Metralindole Indication associated Details
R1296 DB09307 experimental small molecule Oxaprotiline Indication associated Details
R1302 DB09338 experimental small molecule Mersalyl Therapeutic strategy associated Details
R1305 DB09363 investigational small molecule Rauwolfia serpentina root Therapeutic strategy associated Details
R1314 DB09496 approved; investigational small molecule Octinoxate Therapeutic strategy associated Details
R1379 DB11584 approved small molecule Pipradrol Therapeutic strategy associated Details
R1393 DB11700 approved; investigational small molecule Setmelanotide Therapeutic strategy associated Details
R1409 DB11823 approved; investigational small molecule Esketamine Indication associated Details
R1415 DB11859 approved; investigational small molecule Brexanolone Indication associated Details
R1486 DB13178 approved; investigational; withdrawn small molecule Inositol Therapeutic strategy associated Details
R1521 DB14507 approved small molecule Lithium citrate Indication associated Details